From Wikipedia, the free encyclopedia
Jump to navigation Jump to search
Combination of
Dutasteride 5α-Reductase inhibitor
Tamsulosin Alpha-1 blocker
Clinical data
Trade names Combodart, Duodart, Jalyn
Routes of
By mouth
Legal status
Legal status

The combination of dutasteride and tamsulosin, sold under the brand names Combodart, Duodart, and Jalyn, is a medication produced by GlaxoSmithKline for the treatment of adult male symptomatic benign prostatic hyperplasia (BPH).
It is a combination of two previously existing drugs: tamsulosin, brand name Flomax, and dutasteride, brand name Avodart. It contains 0.4 mg of tamsulosin Hydrochloride and 0.5 mg of dutasteride.

Jalyn was the result of the CombAT (Combination of Avodart and Tamsulosin) trial of 2008. It was approved by the FDA on June 14, 2010.[1] In June 2011, the FDA approved a label change warning of "Increased Risk of High-grade Prostate Cancer" from Jalyn.[2]
Since it contains two drugs, it has the drug interactions, side effects and warnings of both drugs.[3]

Jalyn is taken once a day, 30 minutes after the same meal each day.